Bluefin Capital Management’s Atrium Therapeutics RNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$215K Hold
16,011
– – 0.06% 86
2026
Q2
$215K Buy
+16,011
New +$209K 0.05% 93

Other funds holding RNA

Bluefin Capital Management's RNA Position: Q3 2026 in Review

Bluefin Capital Management held its Atrium Therapeutics (RNA) position steady in Q3 2026 at 16,011 shares worth $215K. The position accounts for 0.06% of the portfolio, ranked #86.

Bluefin Capital Management first reported a position in RNA in Q2 2026 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Bluefin Capital Management held 16,011 shares of Atrium Therapeutics worth $215K as of Q3 2026.
  • Bluefin Capital Management left its Atrium Therapeutics share count unchanged in Q3 2026.
  • Atrium Therapeutics made up 0.06% of Bluefin Capital Management's portfolio in Q3 2026, its #86 holding.
  • Bluefin Capital Management first reported a position in Atrium Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Bluefin Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.